2:32 Prevalence studies
3:00 Epidemiological studies
5:48 Reverse causation
07:08 Human lab studies
08:10 Genetic studies
Bhattacharyya, et al.(2009). Modulation of mediotemporal and ventrostriatal function in humans by Delta9-tetrahydrocannabinol: a neural basis for the effects of Cannabis sativa on learning and psychosis. Archives of general psychiatry, 66(4), 442–451.
Bianconi, et al. (2016). Differences in cannabis-related experiences between patients with a first episode of psychosis and controls. Psychological medicine, 46(5), 995–1003.
Bloomfield et al. (2016). The effects of Δ9-tetrahydrocannabinol on the dopamine system. Nature, 539(7629), 369–377.
Bloomfield et al. (2019). The neuropsychopharmacology of cannabis: A review of human imaging studies. Pharmacology & therapeutics, 195, 132–161.
Boydell et al. (2003). Incidence of schizophrenia in south-east London between 1965 and 1997. The British journal of psychiatry : the journal of mental science, 182, 45–49.
Colizzi et al. (2015). Interaction Between Functional Genetic Variation of DRD2 and Cannabis Use on Risk of Psychosis. Schizophrenia bulletin, 41(5), 1171–1182.
D’Souza et al.(2004). The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 29(8), 1558–1572.
Di Forti et al. (2012). Confirmation that the AKT1 (rs2494732) genotype influences the risk of psychosis in cannabis users. Biological psychiatry, 72(10), 811–816.
Di Forti et al. (2015). Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study. The lancet. Psychiatry, 2(3), 233–238.
Di Forti et al. (2019). The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. The lancet. Psychiatry, 6(5), 427–436.
Di Forti et al. (2019). The independent and combined influence of schizophrenia polygenic risk score and heavy cannabis use on risk for psychotic disorder: A case-control analysis from the EUGEI study. bioRxiv, 844803.
Fergusson et al. (2005). Tests of causal linkages between cannabis use and psychotic symptoms. Addiction (Abingdon, England), 100(3), 354–366.
Frisher et al. (2009). Assessing the impact of cannabis use on trends in diagnosed schizophrenia in the United Kingdom from 1996 to 2005. Schizophrenia research, 113(2-3), 123–128.
Gage et al. (2016). Association Between Cannabis and Psychosis: Epidemiologic Evidence. Biological psychiatry, 79(7), 549–556.
Hartz et al. (2014). Comorbidity of severe psychotic disorders with measures of substance use. JAMA psychiatry, 71(3), 248–254.
Hunt et al. (2019). Psychosocial interventions for people with both severe mental illness and substance misuse. Cochrane Database of Systematic Reviews, (12).
Ksir & Hart. (2016). Cannabis and Psychosis: a Critical Overview of the Relationship. Current psychiatry reports, 18(2), 12.
Mensen et al. (2019). Psychopathological symptoms associated with synthetic cannabinoid use: a comparison with natural cannabis. Psychopharmacology, 236(9), 2677–2685.
Miettunen et al. (2008). Association of cannabis use with prodromal symptoms of psychosis in adolescence. The British journal of psychiatry : the journal of mental science, 192(6), 470–471.
Murray et al. (2017). Cannabis-associated psychosis: Neural substrate and clinical impact. Neuropharmacology, 124, 89–104.
Myles et al. (2016). Cannabis use in first episode psychosis: Meta-analysis of prevalence, and the time course of initiation and continued use. The Australian and New Zealand journal of psychiatry, 50(3), 208–219.
Power et al. (2014). Genetic predisposition to schizophrenia associated with increased use of cannabis. Molecular psychiatry, 19(11), 1201–1204.
Reginsson et al. (2018). Polygenic risk scores for schizophrenia and bipolar disorder associate with addiction. Addiction biology, 23(1), 485–492.
Sherif et al. (2016). Human Laboratory Studies on Cannabinoids and Psychosis. Biological psychiatry, 79(7), 526–538.
Stilo & Murray (2019). Non-Genetic Factors in Schizophrenia. Current psychiatry reports, 21(10), 100.
van Amsterdam et al. . (2015). The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects. Journal of psychopharmacology (Oxford, England), 29(3), 254–263.
Verweij et al. (2017). Short communication: Genetic association between schizophrenia and cannabis use. Drug and alcohol dependence, 171, 117–121.
Wang & Krystal (2014). Computational psychiatry. Neuron, 84(3), 638–654.